Shandong Suncadia Medicine (Subsidiary of Jiangsu Hengrui Pharmaceutical) HRS-7535 [58] [58] In a Phase 1 clinical trial conducted by Shandong Suncadia Medicine, a subsidiary of Jiangsu Hengrui Pharmaceutical, the GLP1R agonist HRS-7535 was investigated
When you add a GLP-1 drug to this mix, the drug-drug interaction profile becomes difficult to manage safely
An extremely strong MCAS reaction in a second patient with long COVID and vaccine syndrome (plus antiphospholipid syndrome and major clot risk factors) caused her body to swell up so much that she had trouble eating
That said, its always a good idea to check with your healthcare provider before shifting your schedule, since individual factors like your dosage and any other medications you take can affect whats appropriate for you
Referral pathways typically include general surgery consultation for symptomatic gallstones or cholecystitis, while suspected bile duct stones (choledocholithiasis) or cholangitis may require gastroenterology evaluation for possible endoscopic retrograde cholangiopancreatography (ERCP)
GLP-1 RA use is rising among non-diabetics, raising concerns about misuse
